Next week won't be boring either 🫡

There's something for everyone 😁

What numbers are you looking forward to? 🧐

$MCD (+0,45 %)
$VRTX (-1,11 %)
$KO (+1,37 %)
$SPGI (-4,68 %)
$VRT (-5,62 %)
$PANW (-2,18 %)
$CVS (-1,17 %)

$MEDP (-4,34 %)
$ACLS (-7,84 %)
$THC (-1,22 %)
$TTD (-9,69 %)
$CSCO (-7,73 %)
$APP (-7,89 %)
$HOOD (-6,7 %)
$DE (-3,01 %)
$AMAT (-4,89 %)
$ABNB (-5,88 %)

As announced, here's a little update on January today, nothing long, don't want to bore you

Yield

Yield: 6.82% (FTSE All World: 4.23%)

TTWROR: 7.29%

Thus slightly outperformed, hopefully I can extend this lead further

transactions

Sales:

• Shimano $7309 (-2,09 %)
• 
  Medpace $MEDP (-4,34 %)
• 
  Apple $AAPL (-5,18 %)
• 
  Domino's Pizza $DPZ (-2,28 %)
• 
  McDonald's $MCD (+0,45 %)

Purchases

• Norbit $NORBT (+0,97 %) (subsequent purchase)
• Frosta $NLM (-1,92 %) (initial purchase)
• RCS Mediagroup $RCS (-0,47 %) (initial purchase)
• Uber Technologies $UBER (-2,78 %) (initial purchase)
• Sanlorenzo $SL (-0,54 %) (initial purchase)
• Charles River Labs $CRL (-7,34 %) (subsequent purchase)
• Simply Better Brands $SBBC (-2,32 %) (initial purchase)

Looks like a lot of back and forth for now, but my portfolio conversion is progressing and will soon be completed

During my first year of investing, I bought a lot of shares that I didn't really understand what they were doing. In the course of my restructuring, I would like to reduce my number of shares from almost 30 to 15 in the long term. However, I want to do this over a longer period of time, as these are not bad companies.

Shares that I want to sell

Apple $AAPL (-5,18 %)
Medpace $MEDP (-4,34 %)
ResMed $RMD (-5,99 %)
Shimano $7309 (-2,09 %)
LVMH $MC (-5,25 %)
Genmab $GMAB (+0,79 %)
Pernod Ricard $RI (-1,37 %)
Pilbara Minerals $PLS (-7,55 %)
Sixt $SIX2 (-4,9 %)
McDonald's $MCD (+0,45 %)
Domino's Pizza $DPZ (-2,28 %)
Crowdstrike $CRWD (-3,74 %)
Salesforce $CRM (-4,04 %)
Nvidia $NVDA (-4,64 %)

Just to clarify, I am not selling these companies because they are bad companies, but because they no longer fit into my investment strategy. I will only invest in companies that are not included in the classic world ETFs, but which I nevertheless understand well.

My question would be what you generally think of this and in which order you would sell the companies listed (as they are listed, this is my preferred order)

$MEDP (-4,34 %) Reports Q3 2024

Sales: 533M vs 541M expected (Miss)

EBIT: 112M vs 101M expected (Beat)

Income: 96M vs 90M expected (Beat)

• New Business Awards 533M (Miss) leads to Book-To-Bill of 1.00 down from 1.2-1.3 Range YoY

Outlook for FY24:

Rev: 2.11B vs 2.14B expected (Miss)

EBITDA: 460M vs 450M expected (Beat)

Income: 381M vs 371M expected (Beat)

Expectations were apparently very high. The company is more profitable than expected with less growth. Book-To-Bill is approaching 1. A value below 1 signals a shrinking business, but the backlog is almost 3B, which makes MEDP booked out for a year. So there is still enough time to generate new growth

Hey Community,

$MEDP (-4,34 %) is currently correcting

has anyone bought or currently has an opinion

vg

With a tea content of over 50%, I then have

$ELF (-14,34 %) and. $MEDP (-4,34 %)

sold.

That's called rebalancing 🙈, or maybe not.

Because now it's time to sort out the tech sector and find something new in healthcare.

$MEDP (-4,34 %) Were earnings really that bad? Sales are supposed to be lower, but the bottom line has been raised considerably and the backlog has also grown.

Billings have collapsed, which is probably the reason, but I see a good long-term entry point

And there is an immediate follow-up purchase.

After one foot was already in the door.

PEARL DIVING $MEDP (-4,34 %)

Discover Medpace Hldgs: A closer look

Medpace is an advanced-stage contract research organization that provides comprehensive drug development and clinical trial services to small and mid-sized biotechnology, pharmaceutical and medical device companies. It also offers additional services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and employs over 5,400 people in 40 countries. Medpace is headquartered in Cincinnati and its operations are primarily based in the United States, but it also operates in Europe, Asia, South America, Africa and Australia. Cinven, a global private equity firm, acquired Medpace in 2014 for USD 915 million and exited its investment in 2018.

Medpace Hldgs: Analysis of the financial performance

Market capitalization analysis: The company's market capitalization is below industry benchmarks and is subject to size constraints. This could be influenced by factors such as growth expectations or operating capacity.

Sales Growth: Medpace Hldgs has achieved positive results in 3 months. As of March 31, 2024, the company achieved a solid revenue growth rate of approx. 17,73 % . This indicates a significant increase in the company's revenue. Compared to its industry peers, the company stands out with a growth rate above the average of its peers in the Healthcare sector.

Net margin: The company's net margin is outstanding and outperforms the industry average. With an impressive net margin of 20,07 % the company demonstrates high profitability and effective cost control.

Return on equity (ROE): Medpace Hldgs' financial strength is reflected in its exceptional return on equity, which exceeds the industry average. With a remarkable return on equity of 16,67 % the company demonstrates efficient use of equity and strong financial health.

Return on assets (ROA): Medpace Hldgs' ROA exceeds industry standards and underscores the company's exceptional financial performance. With an impressive return on assets of 5.94 % the company is effectively utilizing its assets for optimal returns.

Debt Management: With a below-average debt-to-equity ratio of 0,2 Medpace Hldgs pursues a prudent financial strategy, which indicates a balanced approach to debt management.

Mizuho starts Medpace with a call option and points to earnings growth potential.

https://seekingalpha.com/news/4110837-mizuho-starts-medpace-at-buy-cites-earnings-growth-potential